{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:58:17Z","timestamp":1780732697079,"version":"3.54.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>\n                    To investigate the causal relationship between follistatin (FST) levels and endocrine diseases such as polycystic ovary syndrome (PCOS), type 2 diabetes (T2DM), obesity, and osteoporosis (OP) using a 2-sample Mendelian randomization (MR) analysis. Instrumental variables closely associated with FST levels were obtained from large-scale genome-wide association study data in the IEU database. Summary-level data for 4 endocrine diseases were sourced from the latest version of the FinnGen database. Our primary method for MR analysis was the inverse-variance weighted (IVW) method, supplemented by the MR-Egger and Weighted Median methods. We conducted a series of sensitivity tests to assess the reliability of our MR results. The IVW analysis revealed a significant causal relationship between elevated levels of FST and both PCOS (odds ratio [OR]\u2005=\u20051.129, 95% confidence interval [CI]: 1.042\u20131.224,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003) and T2DM (OR\u2005=\u20051.103, 95% CI: 1.02\u20131.187,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.01). However, the IVW model did not indicate a causal connection between FST levels and either OP (OR\u2005=\u20051.061, 95% CI: 0.909\u20131.238,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.452) or obesity (OR\u2005=\u20051.082, 95% CI: 0.983\u20131.192,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.108). The reverse MR analysis results indicated a causative association between T2DM (OR\u2005=\u20051.047, 95% CI: 1.006\u20131.089,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.023) and an elevation in FST levels, as well as a causal link between OP (OR\u2005=\u20050.889, 95% CI: 0.804\u20130.982,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.021) and a reduction in FST levels. There is no direct causality between PCOS (OR\u2005=\u20050.925, 95% CI: 0.778\u20131.098,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.372), obesity (OR\u2005=\u20051.035, 95% CI: 0.968\u20131.107,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.312), and FST levels. In addition, our sensitivity tests, which included a pleiotropy test, heterogeneity test, and \u201cleave-one-out\u201d analysis, consistently confirmed the reliability of our results. Genetically predicted high FST levels are causally associated with increased risks of PCOS and T2DM, indicating a potential role in endocrine disease pathogenesis. Moreover, reverse MR analysis revealed a significant causal link between OP and decreased FST levels, suggesting that FST may serve as a promising biomarker or therapeutic target in bone metabolism.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045566","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:01:32Z","timestamp":1763571692000},"page":"e45566","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Follistatin levels and endocrine disorders: A two-sample Mendelian randomization study"],"prefix":"10.1097","volume":"104","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8696-0886","authenticated-orcid":false,"given":"Xinyu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Wenzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/JOE-15-0367","article-title":"Activin A and follistatin during the oestrous cycle and early pregnancy in ewes.","volume":"228","author":"O\u2019Connell","year":"2016","journal-title":"J Endocrinol"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gene.2017.10.017","article-title":"The emerging role of follistatin under stresses and its implications in diseases.","volume":"639","author":"Zhang","year":"2018","journal-title":"Gene"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41591-018-0048-0","article-title":"Inactivating hepatic follistatin alleviates hyperglycemia.","volume":"24","author":"Tao","year":"2018","journal-title":"Nat Med"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.diabet.2019.05.005","article-title":"Regulation of hepatokine gene expression in response to fasting and feeding: influence of PPAR-\u03b1 and insulin-dependent signalling in hepatocytes.","volume":"46","author":"Smati","year":"2020","journal-title":"Diabetes Metabol"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.metabol.2018.05.003","article-title":"Regulation of the activins-follistatins-inhibins axis by energy status: impact on reproductive function.","volume":"85","author":"Perakakis","year":"2018","journal-title":"Metab Clin Exp"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/biolre\/ioz235","article-title":"Role of bone morphogenetic protein signaling in bovine early embryonic development and stage specific embryotropic actions of follistatin\u2020.","volume":"102","author":"Rajput","year":"2020","journal-title":"Biol Reprod"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/jcsm.12474","article-title":"Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle.","volume":"10","author":"Han","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/mend.12.1.0053","article-title":"Overexpression of mouse follistatin causes reproductive defects in transgenic mice.","volume":"12","author":"Guo","year":"1998","journal-title":"Mol Endocrinol"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.96.15.8573","article-title":"Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin.","volume":"96","author":"Urbanek","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"dgaa090","DOI":"10.1210\/clinem\/dgaa090","article-title":"Circulating follistatin and activin a and their regulation by insulin in obesity and type 2 diabetes.","volume":"105","author":"Sylow","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/dmrr.2415","article-title":"Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation.","volume":"29","author":"Hansen","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"410579","DOI":"10.1155\/2012\/410579","article-title":"Correlation between blood activin levels and clinical parameters of type 2 diabetes.","volume":"2012","author":"Wu","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1096\/fj.201801969RR","article-title":"A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice.","volume":"33","author":"Lodberg","year":"2019","journal-title":"FASEB J"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12877-021-02481-7","article-title":"Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women.","volume":"21","author":"Du","year":"2021","journal-title":"BMC Geriatr"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"e2106858119","DOI":"10.1073\/pnas.2106858119","article-title":"Mendelian randomization for causal inference accounting for pleiotropy and sample structure using genome-wide summary statistics.","volume":"119","author":"Hu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"R195","DOI":"10.1093\/hmg\/ddy163","article-title":"Evaluating the potential role of pleiotropy in mendelian randomization studies.","volume":"27","author":"Hemani","year":"2018","journal-title":"Hum Mol Genet"},{"key":"R18-20260520","first-page":"a041302","article-title":"Mendelian randomization.","volume":"12","author":"Birney","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s42255-020-00287-2","article-title":"Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.","volume":"2","author":"Folkersen","year":"2020","journal-title":"Nat Metab"},{"key":"R20-20260520","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nmeth.1974","article-title":"The 1000 Genomes Project: data management and community access.","volume":"9","author":"Clarke","year":"2012","journal-title":"Nat Methods"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1093\/bioinformatics\/btz469","article-title":"PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations.","volume":"35","author":"Kamat","year":"2019","journal-title":"Bioinformatics"},{"key":"R22-20260520","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41467-020-14389-8","article-title":"Physical activity and risks of breast and colorectal cancer: a mendelian randomisation analysis.","volume":"11","author":"Papadimitriou","year":"2020","journal-title":"Nat Commun"},{"key":"R23-20260520","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ng.2528","article-title":"Identification of seven loci affecting mean telomere length and their association with disease.","volume":"45","author":"Codd","year":"2013","journal-title":"Nat Genet"},{"key":"R24-20260520","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyt179","article-title":"Calculating statistical power in Mendelian randomization studies.","volume":"42","author":"Brion","year":"2013","journal-title":"Int J Epidemiol"},{"key":"R26-20260520","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1177\/0962280215597579","article-title":"A review of instrumental variable estimators for mendelian randomization.","volume":"26","author":"Burgess","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"R27-20260520","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ebmental-2019-300085","article-title":"Using Mendelian randomisation to assess causality in observational studies.","volume":"22","author":"Pagoni","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"R28-20260520","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption.","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R29-20260520","doi-asserted-by":"crossref","first-page":"211","DOI":"10.23736\/S0026-4784.19.04404-6","article-title":"Criteria, phenotypes and prevalence of polycystic ovary syndrome.","volume":"71","author":"Belenkaia","year":"2019","journal-title":"Minerva Ginecol"},{"key":"R30-20260520","first-page":"89","article-title":"Polycystic ovary syndrome and metabolic disorders: a review of the literature.","volume":"26","author":"Ali","year":"2022","journal-title":"Afr J Reprod Health"},{"key":"R31-20260520","doi-asserted-by":"crossref","first-page":"e0246200","DOI":"10.1371\/journal.pone.0246200","article-title":"Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.","volume":"16","author":"Raeisi","year":"2021","journal-title":"PLoS One"},{"key":"R32-20260520","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.metabol.2013.05.003","article-title":"Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers.","volume":"62","author":"Teede","year":"2013","journal-title":"Metabolism"},{"key":"R33-20260520","doi-asserted-by":"crossref","first-page":"1125569","DOI":"10.3389\/fendo.2023.1125569","article-title":"Circulating follistatin concentrations in adolescent PCOS: divergent effects of randomized treatments.","volume":"14","author":"D\u00edaz","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R34-20260520","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/humrep\/16.4.668","article-title":"Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome.","volume":"16","author":"Norman","year":"2001","journal-title":"Hum Reprod"},{"key":"R35-20260520","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/humrep\/16.12.2552","article-title":"Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.","volume":"16","author":"Eldar-Geva","year":"2001","journal-title":"Hum Reprod"},{"key":"R36-20260520","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/oxfordjournals.humrep.a136246","article-title":"Follistatin concentrations in follicular fluid of normal and polycystic ovaries.","volume":"10","author":"Erickson","year":"1995","journal-title":"Hum Reprod"},{"key":"R37-20260520","doi-asserted-by":"crossref","first-page":"bvaa032","DOI":"10.1210\/jendso\/bvaa032","article-title":"Toward a treatment normalizing ovulation rate in adolescent girls with polycystic ovary syndrome.","volume":"4","author":"Ib\u00e1\u00f1ez","year":"2020","journal-title":"J Endocr Soc"},{"key":"R38-20260520","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.tem.2018.09.005","article-title":"Central obesity, faster maturation, and \u201cPCOS\u201d in girls.","volume":"29","author":"de Zegher","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"R39-20260520","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2021.e11709","article-title":"Diabetes mellitus: an overview of the types, symptoms, complications and management.","volume":"37","author":"Cloete","year":"2022","journal-title":"Nurs Stand"},{"key":"R40-20260520","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1038\/s41467-021-26536-w","article-title":"Elevated circulating follistatin associates with an increased risk of type 2 diabetes.","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"R41-20260520","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/dom.13572","article-title":"Follistatins in glucose regulation in healthy and obese individuals.","volume":"21","author":"Perakakis","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R42-20260520","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1210\/en.2012-1844","article-title":"Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice.","volume":"154","author":"Ungerleider","year":"2013","journal-title":"Endocrinology"},{"key":"R43-20260520","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1096\/fj.201802059RRR","article-title":"Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes.","volume":"34","author":"Davey","year":"2020","journal-title":"FASEB J"},{"key":"R44-20260520","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/pgm.2003.12.1544","article-title":"Evaluation of obesity. Who are the obese?","volume":"114","author":"Bray","year":"2003","journal-title":"Postgrad Med"},{"key":"R45-20260520","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/oby.23598","article-title":"FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation.","volume":"31","author":"Li","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"R46-20260520","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s11695-020-04580-7","article-title":"Effect of weight loss surgery on biomarkers of angiogenesis in obese patients.","volume":"30","author":"Wiewiora","year":"2020","journal-title":"Obes Surg"},{"key":"R47-20260520","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41366-020-00664-7","article-title":"Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes.","volume":"45","author":"Pham","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"R48-20260520","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis.","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"key":"R49-20260520","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.","volume":"21","author":"Eijken","year":"2007","journal-title":"FASEB J"},{"key":"R50-20260520","doi-asserted-by":"crossref","first-page":"e2111401118","DOI":"10.1073\/pnas.2111401118","article-title":"Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-\u03b2 signaling pathway.","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R51-20260520","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12020-023-03402-x","article-title":"Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.","volume":"81","author":"Anastasilakis","year":"2023","journal-title":"Endocrine"},{"key":"R52-20260520","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3390\/jcm9041150","article-title":"Modification of muscle-related hormones in women with obesity: potential impact on bone metabolism.","volume":"9","author":"Ma\u00efmoun","year":"2020","journal-title":"J Clin Med"},{"key":"R53-20260520","doi-asserted-by":"crossref","first-page":"e210488","DOI":"10.1530\/EC-21-0488","article-title":"In patients with anorexia nervosa, myokine levels are altered but are not associated with bone mineral density loss and bone turnover alteration.","volume":"11","author":"Ma\u00efmoun","year":"2022","journal-title":"Endocr Connect"},{"key":"R54-20260520","first-page":"1226","article-title":"Follistatin is associated with bone mineral density in lean adolescent girls with increased physical activity.","volume":"10","author":"J\u00fcrim\u00e4e","year":"2023","journal-title":"Children (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:00:22Z","timestamp":1779274822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":54,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045566","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2024-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}